In clinical guidelines, such as National Comprehensive Cancer Network guidelines, it is embodied as first therapeutic option the combination of erlotinib and bevacizumab, based on a small clinical trial which included patients with HLRCC. With this case report we bring out another treatment option, not described before, with extraordinary results based on the combination of a check-point inhibitor and a tyrosine-kinase inhibitor, based on theoretical tumor immunogenic environment.
We use cookies on our website to ensure you get the best experience. Read more about our cookies here.
RSS feed for
Preprints: The Multidisciplinary Preprint Platform
Paste the URL in your RSS reader:
https://www.preprints.org/rss
If you want to subscribe our website in subject-wide, you could find the URL by choosing in the following: